^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Ovarian Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2022
    Excerpt:
    Ovarian Cancer...Maintenance Therapy...Bevacizumab alone added as an option for HR deficient
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase I/II clinical study of SHR-A1811 combined regimen for injection in treatment of platinum-sensitive recurrent ovarian cancer

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500109601